Global Olaparib API Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global Olaparib API market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Olaparib API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Olaparib API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Olaparib API market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Olaparib API is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Olaparib API market include Novartis AG, Pfizer, Bayer AG, Transo-Pharm USA LLC, Sun Pharmaceutical Industrial, ScinoPham Taiwan, MSN Laboratories, Exelixis and DR. Reddy's Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Olaparib API, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Olaparib API, also provides the sales of main regions and countries. Of the upcoming market potential for Olaparib API, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Olaparib API sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Olaparib API market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Olaparib API sales, projected growth trends, production technology, application and end-user industry.

Olaparib API Segment by Company

Novartis AG
Pfizer
Bayer AG
Transo-Pharm USA LLC
Sun Pharmaceutical Industrial
ScinoPham Taiwan
MSN Laboratories
Exelixis
DR. Reddy's Laboratories
AstraZeneca
ALP Pharm Beijing
Alembic Pharmaceuticals

Olaparib API Segment by Type

Ovarian Cancer
Prostate Cancer
Breast Cancer
Pancreatic Cancer

Olaparib API Segment by Application

Pharmaceuticals
Biomedical
Others

Olaparib API Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Olaparib API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Olaparib API market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Olaparib API significant trends, drivers, influence factors in global and regions.
6. To analyze Olaparib API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Olaparib API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Olaparib API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Olaparib API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Olaparib API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Olaparib API industry.
Chapter 3: Detailed analysis of Olaparib API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Olaparib API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Olaparib API in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Olaparib API Sales Value (2020-2031)
1.2.2 Global Olaparib API Sales Volume (2020-2031)
1.2.3 Global Olaparib API Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Olaparib API Market Dynamics
2.1 Olaparib API Industry Trends
2.2 Olaparib API Industry Drivers
2.3 Olaparib API Industry Opportunities and Challenges
2.4 Olaparib API Industry Restraints
3 Olaparib API Market by Company
3.1 Global Olaparib API Company Revenue Ranking in 2024
3.2 Global Olaparib API Revenue by Company (2020-2025)
3.3 Global Olaparib API Sales Volume by Company (2020-2025)
3.4 Global Olaparib API Average Price by Company (2020-2025)
3.5 Global Olaparib API Company Ranking (2023-2025)
3.6 Global Olaparib API Company Manufacturing Base and Headquarters
3.7 Global Olaparib API Company Product Type and Application
3.8 Global Olaparib API Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Olaparib API Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Olaparib API Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Olaparib API Market by Type
4.1 Olaparib API Type Introduction
4.1.1 Ovarian Cancer
4.1.2 Prostate Cancer
4.1.3 Breast Cancer
4.1.4 Pancreatic Cancer
4.2 Global Olaparib API Sales Volume by Type
4.2.1 Global Olaparib API Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Olaparib API Sales Volume by Type (2020-2031)
4.2.3 Global Olaparib API Sales Volume Share by Type (2020-2031)
4.3 Global Olaparib API Sales Value by Type
4.3.1 Global Olaparib API Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Olaparib API Sales Value by Type (2020-2031)
4.3.3 Global Olaparib API Sales Value Share by Type (2020-2031)
5 Olaparib API Market by Application
5.1 Olaparib API Application Introduction
5.1.1 Pharmaceuticals
5.1.2 Biomedical
5.1.3 Others
5.2 Global Olaparib API Sales Volume by Application
5.2.1 Global Olaparib API Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Olaparib API Sales Volume by Application (2020-2031)
5.2.3 Global Olaparib API Sales Volume Share by Application (2020-2031)
5.3 Global Olaparib API Sales Value by Application
5.3.1 Global Olaparib API Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Olaparib API Sales Value by Application (2020-2031)
5.3.3 Global Olaparib API Sales Value Share by Application (2020-2031)
6 Olaparib API Regional Sales and Value Analysis
6.1 Global Olaparib API Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Olaparib API Sales by Region (2020-2031)
6.2.1 Global Olaparib API Sales by Region: 2020-2025
6.2.2 Global Olaparib API Sales by Region (2026-2031)
6.3 Global Olaparib API Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Olaparib API Sales Value by Region (2020-2031)
6.4.1 Global Olaparib API Sales Value by Region: 2020-2025
6.4.2 Global Olaparib API Sales Value by Region (2026-2031)
6.5 Global Olaparib API Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Olaparib API Sales Value (2020-2031)
6.6.2 North America Olaparib API Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Olaparib API Sales Value (2020-2031)
6.7.2 Europe Olaparib API Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Olaparib API Sales Value (2020-2031)
6.8.2 Asia-Pacific Olaparib API Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Olaparib API Sales Value (2020-2031)
6.9.2 South America Olaparib API Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Olaparib API Sales Value (2020-2031)
6.10.2 Middle East & Africa Olaparib API Sales Value Share by Country, 2024 VS 2031
7 Olaparib API Country-level Sales and Value Analysis
7.1 Global Olaparib API Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Olaparib API Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Olaparib API Sales by Country (2020-2031)
7.3.1 Global Olaparib API Sales by Country (2020-2025)
7.3.2 Global Olaparib API Sales by Country (2026-2031)
7.4 Global Olaparib API Sales Value by Country (2020-2031)
7.4.1 Global Olaparib API Sales Value by Country (2020-2025)
7.4.2 Global Olaparib API Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Olaparib API Sales Value Growth Rate (2020-2031)
7.5.2 USA Olaparib API Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Olaparib API Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Olaparib API Sales Value Growth Rate (2020-2031)
7.6.2 Canada Olaparib API Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Olaparib API Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Olaparib API Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Olaparib API Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Olaparib API Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Olaparib API Sales Value Growth Rate (2020-2031)
7.8.2 Germany Olaparib API Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Olaparib API Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Olaparib API Sales Value Growth Rate (2020-2031)
7.9.2 France Olaparib API Sales Value Share by Type, 2024 VS 2031
7.9.3 France Olaparib API Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Olaparib API Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Olaparib API Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Olaparib API Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Olaparib API Sales Value Growth Rate (2020-2031)
7.11.2 Italy Olaparib API Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Olaparib API Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Olaparib API Sales Value Growth Rate (2020-2031)
7.12.2 Spain Olaparib API Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Olaparib API Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Olaparib API Sales Value Growth Rate (2020-2031)
7.13.2 Russia Olaparib API Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Olaparib API Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Olaparib API Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Olaparib API Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Olaparib API Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Olaparib API Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Olaparib API Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Olaparib API Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Olaparib API Sales Value Growth Rate (2020-2031)
7.16.2 China Olaparib API Sales Value Share by Type, 2024 VS 2031
7.16.3 China Olaparib API Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Olaparib API Sales Value Growth Rate (2020-2031)
7.17.2 Japan Olaparib API Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Olaparib API Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Olaparib API Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Olaparib API Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Olaparib API Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Olaparib API Sales Value Growth Rate (2020-2031)
7.19.2 India Olaparib API Sales Value Share by Type, 2024 VS 2031
7.19.3 India Olaparib API Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Olaparib API Sales Value Growth Rate (2020-2031)
7.20.2 Australia Olaparib API Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Olaparib API Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Olaparib API Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Olaparib API Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Olaparib API Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Olaparib API Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Olaparib API Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Olaparib API Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Olaparib API Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Olaparib API Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Olaparib API Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Olaparib API Sales Value Growth Rate (2020-2031)
7.24.2 Chile Olaparib API Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Olaparib API Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Olaparib API Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Olaparib API Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Olaparib API Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Olaparib API Sales Value Growth Rate (2020-2031)
7.26.2 Peru Olaparib API Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Olaparib API Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Olaparib API Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Olaparib API Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Olaparib API Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Olaparib API Sales Value Growth Rate (2020-2031)
7.28.2 Israel Olaparib API Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Olaparib API Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Olaparib API Sales Value Growth Rate (2020-2031)
7.29.2 UAE Olaparib API Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Olaparib API Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Olaparib API Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Olaparib API Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Olaparib API Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Olaparib API Sales Value Growth Rate (2020-2031)
7.31.2 Iran Olaparib API Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Olaparib API Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Olaparib API Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Olaparib API Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Olaparib API Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Novartis AG
8.1.1 Novartis AG Comapny Information
8.1.2 Novartis AG Business Overview
8.1.3 Novartis AG Olaparib API Sales, Value and Gross Margin (2020-2025)
8.1.4 Novartis AG Olaparib API Product Portfolio
8.1.5 Novartis AG Recent Developments
8.2 Pfizer
8.2.1 Pfizer Comapny Information
8.2.2 Pfizer Business Overview
8.2.3 Pfizer Olaparib API Sales, Value and Gross Margin (2020-2025)
8.2.4 Pfizer Olaparib API Product Portfolio
8.2.5 Pfizer Recent Developments
8.3 Bayer AG
8.3.1 Bayer AG Comapny Information
8.3.2 Bayer AG Business Overview
8.3.3 Bayer AG Olaparib API Sales, Value and Gross Margin (2020-2025)
8.3.4 Bayer AG Olaparib API Product Portfolio
8.3.5 Bayer AG Recent Developments
8.4 Transo-Pharm USA LLC
8.4.1 Transo-Pharm USA LLC Comapny Information
8.4.2 Transo-Pharm USA LLC Business Overview
8.4.3 Transo-Pharm USA LLC Olaparib API Sales, Value and Gross Margin (2020-2025)
8.4.4 Transo-Pharm USA LLC Olaparib API Product Portfolio
8.4.5 Transo-Pharm USA LLC Recent Developments
8.5 Sun Pharmaceutical Industrial
8.5.1 Sun Pharmaceutical Industrial Comapny Information
8.5.2 Sun Pharmaceutical Industrial Business Overview
8.5.3 Sun Pharmaceutical Industrial Olaparib API Sales, Value and Gross Margin (2020-2025)
8.5.4 Sun Pharmaceutical Industrial Olaparib API Product Portfolio
8.5.5 Sun Pharmaceutical Industrial Recent Developments
8.6 ScinoPham Taiwan
8.6.1 ScinoPham Taiwan Comapny Information
8.6.2 ScinoPham Taiwan Business Overview
8.6.3 ScinoPham Taiwan Olaparib API Sales, Value and Gross Margin (2020-2025)
8.6.4 ScinoPham Taiwan Olaparib API Product Portfolio
8.6.5 ScinoPham Taiwan Recent Developments
8.7 MSN Laboratories
8.7.1 MSN Laboratories Comapny Information
8.7.2 MSN Laboratories Business Overview
8.7.3 MSN Laboratories Olaparib API Sales, Value and Gross Margin (2020-2025)
8.7.4 MSN Laboratories Olaparib API Product Portfolio
8.7.5 MSN Laboratories Recent Developments
8.8 Exelixis
8.8.1 Exelixis Comapny Information
8.8.2 Exelixis Business Overview
8.8.3 Exelixis Olaparib API Sales, Value and Gross Margin (2020-2025)
8.8.4 Exelixis Olaparib API Product Portfolio
8.8.5 Exelixis Recent Developments
8.9 DR. Reddy's Laboratories
8.9.1 DR. Reddy's Laboratories Comapny Information
8.9.2 DR. Reddy's Laboratories Business Overview
8.9.3 DR. Reddy's Laboratories Olaparib API Sales, Value and Gross Margin (2020-2025)
8.9.4 DR. Reddy's Laboratories Olaparib API Product Portfolio
8.9.5 DR. Reddy's Laboratories Recent Developments
8.10 AstraZeneca
8.10.1 AstraZeneca Comapny Information
8.10.2 AstraZeneca Business Overview
8.10.3 AstraZeneca Olaparib API Sales, Value and Gross Margin (2020-2025)
8.10.4 AstraZeneca Olaparib API Product Portfolio
8.10.5 AstraZeneca Recent Developments
8.11 ALP Pharm Beijing
8.11.1 ALP Pharm Beijing Comapny Information
8.11.2 ALP Pharm Beijing Business Overview
8.11.3 ALP Pharm Beijing Olaparib API Sales, Value and Gross Margin (2020-2025)
8.11.4 ALP Pharm Beijing Olaparib API Product Portfolio
8.11.5 ALP Pharm Beijing Recent Developments
8.12 Alembic Pharmaceuticals
8.12.1 Alembic Pharmaceuticals Comapny Information
8.12.2 Alembic Pharmaceuticals Business Overview
8.12.3 Alembic Pharmaceuticals Olaparib API Sales, Value and Gross Margin (2020-2025)
8.12.4 Alembic Pharmaceuticals Olaparib API Product Portfolio
8.12.5 Alembic Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Olaparib API Value Chain Analysis
9.1.1 Olaparib API Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Olaparib API Sales Mode & Process
9.2 Olaparib API Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Olaparib API Distributors
9.2.3 Olaparib API Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings